Moreover, ApoA5 ASO-treated mice also exhibited protection from HFD-induced hepatic insulin resistance, as reflected by lower rates of endogenous glucose production (EGP) during the hyperinsulinemic-euglycemic clamp compared with control HFD mice (Fig. 4E), reflecting preserved suppression of hepatic glucose production by insulin in the ApoA5 ASO-treated mice (Fig. 4F). Here, APOA5 is linked to Insulin resistance.